Five Prime Therapeutics (FPRX) Stock Price Down 6.4%

Five Prime Therapeutics Inc (NASDAQ:FPRX) shares traded down 6.4% on Wednesday . The stock traded as low as $17.66 and last traded at $17.68. 629,705 shares changed hands during mid-day trading, an increase of 15% from the average session volume of 546,406 shares. The stock had previously closed at $18.89.

Several research analysts have weighed in on the company. Zacks Investment Research downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. BidaskClub upgraded Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. ValuEngine downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, BMO Capital Markets boosted their price target on Five Prime Therapeutics from $71.00 to $75.00 and gave the company an “outperform” rating in a report on Tuesday, November 7th. Three research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Five Prime Therapeutics presently has an average rating of “Hold” and a consensus price target of $64.00.

The stock has a market cap of $601.31, a price-to-earnings ratio of -3.49 and a beta of 3.56.

A number of institutional investors and hedge funds have recently modified their holdings of FPRX. Oppenheimer & Co. Inc. acquired a new stake in shares of Five Prime Therapeutics during the 3rd quarter worth $223,000. Dupont Capital Management Corp acquired a new stake in shares of Five Prime Therapeutics during the 3rd quarter worth $341,000. Teacher Retirement System of Texas acquired a new stake in shares of Five Prime Therapeutics during the 4th quarter worth $221,000. Voya Investment Management LLC increased its holdings in shares of Five Prime Therapeutics by 9.5% during the 2nd quarter. Voya Investment Management LLC now owns 12,594 shares of the biotechnology company’s stock worth $379,000 after buying an additional 1,097 shares during the last quarter. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of Five Prime Therapeutics during the 4th quarter worth $294,000. Institutional investors own 73.98% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Five Prime Therapeutics (FPRX) Stock Price Down 6.4%” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2018/02/21/five-prime-therapeutics-fprx-stock-price-down-6-4.html.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply